Skip to Content

Case Overview

Status:Status:Investigating
Company Name:Company Name:Celcuity Inc.
Ticker:Ticker:CELC
Related Attorneys:Lead Attorneys:Thomas W. Elrod
Related Practices:Related Practices:Securities
On July 14, 2026, Celcuity issued a press release announcing that it had secured U.S. Food and Drug Administration approval for its breast cancer therapy Revtorpyk (gedatolisib) and “anticipates commercial launch in late Q3 2026,” representing a delayed launch timeline relative to analyst expectations.  Commenting on the release, Stifel Financial Corp. analyst Stephen Wiley noted that “late 3Q26 launch guidance seems somewhat extended.” Leerink Partners analyst Andrew Berens agreed, noting that while the “approval was largely expected . . . we did not anticipate [a Q3 launch date] given prior commentary on launch readiness.”
 
On this news, Celcuity’s stock price fell $19.54 per share, or 17.6%, to close at $91.51 per share on July 15, 2026.

Contact Us About This Case

You may share a link to this page on any of the sites listed below or send link via email: